Johnson & Johnson's ICOTYDE® Shows Promising Two-Year Results in Psoriasis Treatment

Transforming Psoriasis Treatment: Two Years of ICOTYDE® (icotrokinra) Results

Johnson & Johnson has unveiled new and compelling results from the Phase 3 ICONIC-LEAD clinical study that focus on their novel treatment, ICOTYDE® (icotrokinra), specifically aimed at addressing moderate-to-severe plaque psoriasis in both adults and adolescents aged 12 and older. This treatment, which uniquely functions as a targeted oral peptide inhibiting the IL-23 receptor, has marked a significant breakthrough in the management of plaque psoriasis. Presented at the 2026 Fall Clinical Dermatology conference, the data show remarkable outcomes that are revolutionizing the current therapeutic landscape.

Long-Term Efficacy

The two-year findings demonstrate high and sustained response rates, with nearly 75% of the treated patient population achieving clear or nearly clear skin after 112 weeks of treatment. Specifically, results revealed that over 72% of patients reached a Psoriasis Area and Severity Index (PASI) score of 90, while more than 70% achieved a score indicating clear or almost clear skin according to the Investigator’s Global Assessment (IGA). These statistics suggest not only efficacy but also the long-lasting effects of ICOTYDE®, as patients maintained skin clearance from earlier time points, specifically from week 64 through week 112.

Additional Symptom Improvements

Patients also reported significant relief from itching, with 78% demonstrating meaningful improvement extending from week 64 to week 112. The durability of the treatments is highlighted by the fact that among those whose treatment was paused at week 24, an impressive 85% regained their PASI 90 response following re-initiation of therapy within 24 weeks.

Safety Profile Remains Positive

The safety data collected throughout this period continues to reinforce the established favorable safety profile of ICOTYDE®, with no new safety signals reported. This is particularly reassuring given the critical nature of chronic conditions like plaque psoriasis, where treatment options must balance efficacy with patient safety. Dr. David M. Lee, who heads the Global Immunology Therapeutic Area at Johnson & Johnson, emphasized the transformative potential of ICOTYDE®, highlighting how its consistent and effective long-term management addresses the unmet needs of these patients.

The Importance of Accessibility

Plaque psoriasis — a chronic, immune-mediated disease characterized by extensive skin plaques — affects approximately 8 million individuals in the U.S., with more than 125 million worldwide. Given that nearly a quarter of these patients contend with moderate-to-severe manifestations of the disease, treatments like ICOTYDE® are vital for improving the quality of life. The consequences of living with visible and often painful skin lesions extend beyond physical symptoms, affecting emotional and psychological well-being, potentially leading to challenges in social interactions and overall life satisfaction.

Administration and Recommendations

ICOTYDE® is administered orally, with a simple regimen of taking one pill each day on an empty stomach, ensuring adherence and convenience for patients. This approach marks a shift towards more patient-friendly treatment modalities in serious conditions, offering hope to many who struggle with the burdens of psoriasis.

Conclusion

The results presented by Johnson & Johnson at the Fall Clinical Dermatology conference affirm the potential of ICOTYDE® as a first-line systemic therapy for those affected by moderate-to-severe plaque psoriasis. By prioritizing patient-centric approaches and innovative therapies, the company aims to uphold its commitment to enhancing healthcare outcomes for individuals grappling with chronic diseases. Continued studies will further elucidate ICOTYDE's versatility, as it is also being tested for applications beyond psoriasis, including psoriatic arthritis and inflammatory bowel diseases. The future looks promising as the scientific community eagerly anticipates further developments stemming from the ICONIC clinical program.